The graft:

• Based on a unique 3D stable matrix technology
• Consists of two components: an absorbable gel-textile-matrix and autologous in vitro seeded chondrocytes
• Is mechanically stable and flexible
• Has a size of 20 x 30 x 1,1 mm
• Contains 28.8 millions autologous in vitro expanded chondrocytes
• Is available for the patient approx. 4-5 weeks from patient’s biopsy delivery
• Is manufactured and distributed according to the current requirements of the German Drugs Law and the European GMP standards (Good Manufacturing Practice)

The application:

• For the first time with BioSeed®-C a chondrocytes graft can be fixed to the subchondral bone in a secure way
• This makes it possible to treat defects without intact cartilage rims
• The graft can be cut to fit the size of the cartilage defect
• BioSeed®-C has no orientation: cells are evenly distributed for an easier handling
• The transplantation can be done by arthroscopy or by arthrothomy

The results:

• The absorbable matrix dissoves in 4-6 months after transplantation
• In the meanwhile hyaline cartilage grows and evenly fills the cartilage damage
• In numerous studies a significant improvement of clinical parameters could be reported also in the long term